EU steps closer to generics and biosimilars manufacturing waiver

A change to European rules on drug manufacturing that could benefit makers of generics and biosimilars is edging closer, after lawmakers agreed draft legislation that tweaks rules on export and manufacture of drugs that are off-patent outside the EU. The draft of the so-called supplementary protection certificate (SPC) waiver legislation has been agreed at a committee earlier this month.
Read more...

;